PERTH, Australia – Imugene Ltd. has closed an AU$90 million (US$64 million) placement and an AU$5 million share repurchase plan that will allow the company to progress its CAR T pipeline through 2025 and pursue a collaboration with Celgene Corp. spin-off Celularity Inc.
Suzhou Abogen Biosciences Co. Ltd.’s $700 million series C fundraising provides tailwinds for the development of its messenger ribonucleic acid (mRNA) platform. The company plans to accelerate its COVID-19 mRNA vaccine clinical trial, develop other vaccine candidates and oncology programs.
Opya Inc., a provider of integrated autism services, secured $15.4 million in a series A fundraising round. New investors in the round included Panoramic Ventures, Softbank’s Opportunity Fund, Disability Opportunity Fund, and Raven One Ventures. Divergent Investments and Altitude Ventures added to their existing investments in the company.
Vigil Neuroscience Inc. CEO Ivana Magovčević-Liebisch said the just-raised $90 million in series B money will let the company reach “a lot of value-generating milestones,” having been “moving extremely fast” in the year since it was founded.
Immunitas Therapeutics Inc., a company leveraging single cell analysis to identify and validate new drug targets, has closed $58 million in series B financing led by Agent Capital. The funds will be used to advance its lead program, the CD161 inhibitor IMT-009, into the clinic for testing against both solid tumors and hematological malignancies, pending approval of a forthcoming IND filing next year.
Jnana Therapeutics Inc. closed a $50 million series B round and took the covers off its lead program, a small-molecule inhibitor of the solute carrier transporter SLC6A19, which it is prepping for clinical trials in phenylketonuria (PKU).
RSS
